EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
